speb/financial-data huggingface dataset:
MRNA cash_flow (annual, 2024-12-31) — Net Issuance Payments Of Debt: -10000000.00
MRNA cash_flow (annual, 2024-12-31) — Net Long Term Debt Issuance: -10000000.00
MRNA income_statement (annual, 2024-12-31) — Net Non Operating Interest Income Expense: 401000000.00
MRNA balance_sheet (annual, 2024-12-31) — Net PPE: 2955000000.00
MRNA cash_flow (annual, 2024-12-31) — Net PPE Purchase And Sale: -1051000000.00
MRNA balance_sheet (annual, 2024-12-31) — Net Tangible Assets: 10809000000.00
MRNA balance_sheet (annual, 2024-12-31) — Non Current Accounts Receivable: 97000000.00
MRNA balance_sheet (annual, 2024-12-31) — Non Current Deferred Assets: 81000000.00
MRNA balance_sheet (annual, 2024-12-31) — Non Current Deferred Liabilities: 58000000.00
MRNA balance_sheet (annual, 2024-12-31) — Non Current Deferred Revenue: 58000000.00
MRNA balance_sheet (annual, 2024-12-31) — Non Current Deferred Taxes Assets: 81000000.00
MRNA balance_sheet (annual, 2024-12-31) — Non Current Prepaid Assets: 139000000.00
MRNA income_statement (annual, 2024-12-31) — Normalized EBITDA: -3338000000.00
MRNA income_statement (annual, 2024-12-31) — Normalized Income: -3505714166.90
MRNA cash_flow (annual, 2024-12-31) — Operating Cash Flow: -3004000000.00
MRNA cash_flow (annual, 2024-12-31) — Operating Gains Losses: 52000000.00
MRNA income_statement (annual, 2024-12-31) — Operating Income: -3945000000.00
MRNA income_statement (annual, 2024-12-31) — Operating Revenue: 4517000000.00
MRNA balance_sheet (annual, 2024-12-31) — Ordinary Shares Number: 386000000.00
MRNA balance_sheet (annual, 2024-12-31) — Other Current Assets: 58000000.00
MRNA balance_sheet (annual, 2024-12-31) — Other Current Liabilities: 184000000.00
MRNA balance_sheet (annual, 2024-12-31) — Other Equity Adjustments: -10000000.00
MRNA income_statement (annual, 2024-12-31) — Other Income Expense: -63000000.00
MRNA income_statement (quarterly, 2024-12-31) — Other Income Expense: -23000000.00
MRNA balance_sheet (annual, 2024-12-31) — Other Intangible Assets: 40000000.00
MRNA cash_flow (annual, 2024-12-31) — Other Non Cash Items: 60000000.00
MRNA balance_sheet (annual, 2024-12-31) — Other Non Current Assets: 171000000.00
MRNA balance_sheet (annual, 2024-12-31) — Other Non Current Liabilities: 36000000.00
MRNA income_statement (annual, 2024-12-31) — Other Non Operating Income Expenses: -7000000.00
MRNA income_statement (quarterly, 2024-12-31) — Other Non Operating Income Expenses: -14000000.00
MRNA income_statement (annual, 2024-12-31) — Other Operating Expenses: -37000000.00
MRNA income_statement (quarterly, 2024-12-31) — Other Operating Expenses: -10000000.00
MRNA balance_sheet (annual, 2024-12-31) — Other Properties: 1235000000.00
MRNA balance_sheet (annual, 2024-12-31) — Other Receivables: 58000000.00
MRNA balance_sheet (annual, 2024-12-31) — Other Short Term Investments: 5098000000.00
MRNA balance_sheet (annual, 2024-12-31) — Payables: 405000000.00
MRNA balance_sheet (annual, 2024-12-31) — Payables And Accrued Expenses: 1150000000.00
MRNA balance_sheet (annual, 2024-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 312000000.00
MRNA balance_sheet (annual, 2024-12-31) — Preferred Stock: 0.00
MRNA balance_sheet (annual, 2024-12-31) — Prepaid Assets: 307000000.00
MRNA income_statement (annual, 2024-12-31) — Pretax Income: -3607000000.00
MRNA balance_sheet (annual, 2024-12-31) — Properties: 0.00
MRNA cash_flow (annual, 2024-12-31) — Purchase Of Business: 0.00
MRNA cash_flow (quarterly, 2024-12-31) — Purchase Of Business: 0.00
MRNA cash_flow (annual, 2024-12-31) — Purchase Of Intangibles: 0.00
MRNA cash_flow (annual, 2024-12-31) — Purchase Of Investment: -6529000000.00
MRNA cash_flow (annual, 2024-12-31) — Purchase Of PPE: -1051000000.00
MRNA balance_sheet (annual, 2024-12-31) — Raw Materials: 63000000.00
MRNA balance_sheet (annual, 2024-12-31) — Receivables: 592000000.00
MRNA income_statement (annual, 2024-12-31) — Reconciled Cost Of Revenue: 1464000000.00
MRNA income_statement (annual, 2024-12-31) — Reconciled Depreciation: 189000000.00
MRNA cash_flow (annual, 2024-12-31) — Repayment Of Debt: 0.00
MRNA cash_flow (annual, 2024-12-31) — Repurchase Of Capital Stock: 0.00
MRNA cash_flow (quarterly, 2024-12-31) — Repurchase Of Capital Stock: 0.00
MRNA income_statement (annual, 2024-12-31) — Research And Development: 4543000000.00
MRNA balance_sheet (annual, 2024-12-31) — Retained Earnings: 10045000000.00
MRNA cash_flow (annual, 2024-12-31) — Sale Of Investment: 9529000000.00
MRNA income_statement (annual, 2024-12-31) — Selling General And Administration: 1174000000.00
MRNA balance_sheet (annual, 2024-12-31) — Share Issued: 386000000.00
MRNA cash_flow (annual, 2024-12-31) — Stock Based Compensation: 429000000.00
MRNA balance_sheet (annual, 2024-12-31) — Stockholders Equity: 10901000000.00
MRNA balance_sheet (annual, 2024-12-31) — Tangible Book Value: 10809000000.00
MRNA income_statement (annual, 2024-12-31) — Tax Effect Of Unusual Items: -714166.90
MRNA income_statement (annual, 2024-12-31) — Tax Provision: -46000000.00
MRNA income_statement (annual, 2024-12-31) — Tax Rate For Calcs: 0.01
MRNA balance_sheet (annual, 2024-12-31) — Taxes Receivable: 117000000.00
MRNA balance_sheet (annual, 2024-12-31) — Total Assets: 14142000000.00
MRNA balance_sheet (annual, 2024-12-31) — Total Capitalization: 10901000000.00
MRNA balance_sheet (annual, 2024-12-31) — Total Debt: 747000000.00
MRNA balance_sheet (annual, 2024-12-31) — Total Equity Gross Minority Interest: 10901000000.00
MRNA income_statement (annual, 2024-12-31) — Total Expenses: 7144000000.00
MRNA balance_sheet (annual, 2024-12-31) — Total Liabilities Net Minority Interest: 3241000000.00
MRNA balance_sheet (annual, 2024-12-31) — Total Non Current Assets: 6043000000.00
MRNA balance_sheet (annual, 2024-12-31) — Total Non Current Liabilities Net Minority Interest: 1035000000.00
MRNA income_statement (annual, 2024-12-31) — Total Operating Income As Reported: -3945000000.00
MRNA balance_sheet (annual, 2024-12-31) — Total Tax Payable: 3000000.00
MRNA balance_sheet (quarterly, 2024-12-31) — Total Tax Payable: 3000000.00
MRNA income_statement (annual, 2024-12-31) — Total Unusual Items: -56000000.00
MRNA income_statement (quarterly, 2024-12-31) — Total Unusual Items: -9000000.00
MRNA income_statement (annual, 2024-12-31) — Total Unusual Items Excluding Goodwill: -56000000.00
MRNA income_statement (quarterly, 2024-12-31) — Total Unusual Items Excluding Goodwill: -9000000.00
MRNA balance_sheet (annual, 2024-12-31) — Tradeand Other Payables Non Current: 231000000.00
MRNA balance_sheet (annual, 2024-12-31) — Work In Process: 26000000.00
MRNA balance_sheet (annual, 2024-12-31) — Working Capital: 5893000000.00
MRNA income_statement (quarterly, 2025-03-31) — +Operating Expense: 1067000000.00
MRNA income_statement (quarterly, 2025-03-31) — +Total Revenue: 107000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 226000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 78000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Accrued Interest Receivable: 53000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Accumulated Depreciation: -566000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 982000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -171000000.00
MRNA cash_flow (quarterly, 2025-03-31) — Amortization Of Securities: -19000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Available For Sale Securities: 2418000000.00
MRNA income_statement (quarterly, 2025-03-31) — Basic Average Shares: 386000000.00
MRNA income_statement (quarterly, 2025-03-31) — Basic EPS: -2.52
MRNA cash_flow (quarterly, 2025-03-31) — Beginning Cash Position: 1929000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Buildings And Improvements: 759000000.00
MRNA cash_flow (quarterly, 2025-03-31) — Capital Expenditure: -127000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Capital Lease Obligations: 745000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Capital Stock: 0.00
MRNA balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 1623000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 5975000000.00
MRNA cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Financing Activities: 4000000.00
MRNA cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Investing Activities: 730000000.00
MRNA cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Operating Activities: -1037000000.00
MRNA cash_flow (quarterly, 2025-03-31) — Change In Account Payable: -156000000.00
MRNA cash_flow (quarterly, 2025-03-31) — Change In Accrued Expense: -381000000.00
MRNA cash_flow (quarterly, 2025-03-31) — Change In Inventory: -8000000.00
MRNA cash_flow (quarterly, 2025-03-31) — Change In Other Current Assets: 9000000.00
MRNA cash_flow (quarterly, 2025-03-31) — Change In Other Current Liabilities: 28000000.00
MRNA cash_flow (quarterly, 2025-03-31) — Change In Other Working Capital: -29000000.00
MRNA cash_flow (quarterly, 2025-03-31) — Change In Payable: -156000000.00
MRNA cash_flow (quarterly, 2025-03-31) — Change In Payables And Accrued Expense: -537000000.00
MRNA cash_flow (quarterly, 2025-03-31) — Change In Prepaid Assets: 46000000.00
MRNA cash_flow (quarterly, 2025-03-31) — Change In Receivables: 280000000.00
MRNA cash_flow (quarterly, 2025-03-31) — Change In Working Capital: -211000000.00
MRNA cash_flow (quarterly, 2025-03-31) — Changes In Account Receivables: 280000000.00
MRNA cash_flow (quarterly, 2025-03-31) — Changes In Cash: -303000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Common Stock: 0.00
MRNA balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 10066000000.00
MRNA cash_flow (quarterly, 2025-03-31) — Common Stock Issuance: 3000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Construction In Progress: 1078000000.00
MRNA income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 90000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Current Accrued Expenses: 544000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Current Assets: 6766000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Current Capital Lease Obligation: 43000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 43000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Current Deferred Liabilities: 125000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Current Deferred Revenue: 125000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 1604000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Current Provisions: 337000000.00
MRNA cash_flow (quarterly, 2025-03-31) — Depreciation Amortization Depletion: 39000000.00
MRNA cash_flow (quarterly, 2025-03-31) — Depreciation And Amortization: 39000000.00
MRNA income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 386000000.00
MRNA income_statement (quarterly, 2025-03-31) — Diluted EPS: -2.52
MRNA income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: -971000000.00
MRNA income_statement (quarterly, 2025-03-31) — EBIT: -963000000.00
MRNA income_statement (quarterly, 2025-03-31) — EBITDA: -924000000.00
MRNA cash_flow (quarterly, 2025-03-31) — Earnings Losses From Equity Investments: 8000000.00
MRNA cash_flow (quarterly, 2025-03-31) — Effect Of Exchange Rate Changes: 0.00
MRNA cash_flow (quarterly, 2025-03-31) — End Cash Position: 1626000000.00
MRNA cash_flow (quarterly, 2025-03-31) — Financing Cash Flow: 4000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Finished Goods: 14000000.00
MRNA cash_flow (quarterly, 2025-03-31) — Free Cash Flow: -1164000000.00
MRNA income_statement (quarterly, 2025-03-31) — Gain On Sale Of Security: -7000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Gains Losses Not Affecting Retained Earnings: 10000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Goodwill: 52000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 101000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Gross Accounts Receivable: 249000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Gross PPE: 3530000000.00
MRNA income_statement (quarterly, 2025-03-31) — Gross Profit: 17000000.00
MRNA income_statement (quarterly, 2025-03-31) — Interest Expense: 1000000.00
MRNA income_statement (quarterly, 2025-03-31) — Interest Expense Non Operating: 1000000.00
MRNA income_statement (quarterly, 2025-03-31) — Interest Income: 90000000.00
MRNA income_statement (quarterly, 2025-03-31) — Interest Income Non Operating: 90000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Inventory: 128000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Invested Capital: 10066000000.00
MRNA cash_flow (quarterly, 2025-03-31) — Investing Cash Flow: 730000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Investmentin Financial Assets: 2418000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Investments And Advances: 2424000000.00
MRNA cash_flow (quarterly, 2025-03-31) — Issuance Of Capital Stock: 3000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Land And Improvements: 59000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Leases: 208000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Long Term Capital Lease Obligation: 702000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 702000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Long Term Equity Investment: 6000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Machinery Furniture Equipment: 181000000.00
MRNA cash_flow (quarterly, 2025-03-31) — Net Common Stock Issuance: 3000000.00
MRNA income_statement (quarterly, 2025-03-31) — Net Income: -971000000.00
MRNA income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: -971000000.00
MRNA income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: -971000000.00
MRNA income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: -971000000.00
MRNA income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: -971000000.00
MRNA cash_flow (quarterly, 2025-03-31) — Net Income From Continuing Operations: -971000000.00
MRNA income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: -971000000.00
MRNA cash_flow (quarterly, 2025-03-31) — Net Intangibles Purchase And Sale: -10000000.00
MRNA income_statement (quarterly, 2025-03-31) — Net Interest Income: 89000000.00
MRNA cash_flow (quarterly, 2025-03-31) — Net Investment Purchase And Sale: 857000000.00
MRNA cash_flow (quarterly, 2025-03-31) — Net Issuance Payments Of Debt: 2000000.00
MRNA cash_flow (quarterly, 2025-03-31) — Net Long Term Debt Issuance: 2000000.00
MRNA income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: 89000000.00
MRNA cash_flow (quarterly, 2025-03-31) — Net Other Financing Charges: -1000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Net PPE: 2964000000.00
MRNA cash_flow (quarterly, 2025-03-31) — Net PPE Purchase And Sale: -117000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 9965000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Non Current Accounts Receivable: 99000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Assets: 81000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Liabilities: 58000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Revenue: 58000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Assets: 81000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Non Current Prepaid Assets: 119000000.00
MRNA income_statement (quarterly, 2025-03-31) — Normalized EBITDA: -917000000.00
MRNA income_statement (quarterly, 2025-03-31) — Normalized Income: -965470000.00
MRNA cash_flow (quarterly, 2025-03-31) — Operating Cash Flow: -1037000000.00
MRNA cash_flow (quarterly, 2025-03-31) — Operating Gains Losses: 8000000.00
MRNA income_statement (quarterly, 2025-03-31) — Operating Income: -1050000000.00
MRNA income_statement (quarterly, 2025-03-31) — Operating Revenue: 105000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 386622604.00
MRNA balance_sheet (quarterly, 2025-03-31) — Other Current Assets: 69000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Other Current Liabilities: 209000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Other Equity Adjustments: 10000000.00
MRNA income_statement (quarterly, 2025-03-31) — Other Income Expense: -3000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Other Intangible Assets: 49000000.00
MRNA cash_flow (quarterly, 2025-03-31) — Other Non Cash Items: 2000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Other Non Current Assets: 150000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Other Non Current Liabilities: 40000000.00
MRNA income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: 4000000.00
MRNA income_statement (quarterly, 2025-03-31) — Other Operating Expenses: -1000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Other Properties: 1245000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Other Receivables: 58000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Other Short Term Investments: 4352000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Payables: 226000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Payables And Accrued Expenses: 770000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 120000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Preferred Stock: 0.00
MRNA balance_sheet (quarterly, 2025-03-31) — Prepaid Assets: 288000000.00
MRNA income_statement (quarterly, 2025-03-31) — Pretax Income: -964000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Properties: 0.00
MRNA cash_flow (quarterly, 2025-03-31) — Purchase Of Intangibles: -10000000.00
MRNA cash_flow (quarterly, 2025-03-31) — Purchase Of Investment: -1764000000.00
MRNA cash_flow (quarterly, 2025-03-31) — Purchase Of PPE: -117000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Raw Materials: 75000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Receivables: 306000000.00
MRNA income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 90000000.00
MRNA income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 39000000.00
MRNA income_statement (quarterly, 2025-03-31) — Research And Development: 856000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Retained Earnings: 9074000000.00
MRNA cash_flow (quarterly, 2025-03-31) — Sale Of Investment: 2621000000.00
MRNA income_statement (quarterly, 2025-03-31) — Selling General And Administration: 212000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Share Issued: 386622604.00
MRNA cash_flow (quarterly, 2025-03-31) — Stock Based Compensation: 115000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 10066000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 9965000000.00
MRNA income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: -1470000.00
MRNA income_statement (quarterly, 2025-03-31) — Tax Provision: 7000000.00
MRNA income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.21
MRNA balance_sheet (quarterly, 2025-03-31) — Taxes Receivable: 117000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Total Assets: 12704000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 10066000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Total Debt: 745000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 10066000000.00
MRNA income_statement (quarterly, 2025-03-31) — Total Expenses: 1157000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 2638000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 5938000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 1034000000.00
MRNA income_statement (quarterly, 2025-03-31) — Total Operating Income As Reported: -1050000000.00
MRNA income_statement (quarterly, 2025-03-31) — Total Unusual Items: -7000000.00
MRNA income_statement (quarterly, 2025-03-31) — Total Unusual Items Excluding Goodwill: -7000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Tradeand Other Payables Non Current: 234000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Work In Process: 39000000.00
MRNA balance_sheet (quarterly, 2025-03-31) — Working Capital: 5162000000.00
MRNA income_statement (quarterly, 2025-06-30) — +Operating Expense: 925000000.00
MRNA income_statement (quarterly, 2025-06-30) — +Total Revenue: 137000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Accounts Payable: 175000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Accounts Receivable: 36000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Accrued Interest Receivable: 47000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Accumulated Depreciation: -623000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Additional Paid In Capital: 1127000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Allowance For Doubtful Accounts Receivable: -224000000.00
MRNA cash_flow (quarterly, 2025-06-30) — Amortization Of Securities: -18000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Available For Sale Securities: 2374000000.00
MRNA income_statement (quarterly, 2025-06-30) — Basic Average Shares: 388000000.00
MRNA income_statement (quarterly, 2025-06-30) — Basic EPS: -2.13
MRNA cash_flow (quarterly, 2025-06-30) — Beginning Cash Position: 1626000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Buildings And Improvements: 798000000.00
MRNA cash_flow (quarterly, 2025-06-30) — Capital Expenditure: -3000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Capital Lease Obligations: 741000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Capital Stock: 0.00
MRNA balance_sheet (quarterly, 2025-06-30) — Cash And Cash Equivalents: 1279000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Cash Cash Equivalents And Short Term Investments: 5131000000.00
MRNA cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Financing Activities: 9000000.00
MRNA cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Investing Activities: 564000000.00
MRNA cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Operating Activities: -919000000.00
MRNA cash_flow (quarterly, 2025-06-30) — Change In Account Payable: -47000000.00
MRNA cash_flow (quarterly, 2025-06-30) — Change In Accrued Expense: -14000000.00
MRNA cash_flow (quarterly, 2025-06-30) — Change In Inventory: -114000000.00
MRNA cash_flow (quarterly, 2025-06-30) — Change In Other Current Assets: 10000000.00
MRNA cash_flow (quarterly, 2025-06-30) — Change In Other Current Liabilities: -63000000.00
MRNA cash_flow (quarterly, 2025-06-30) — Change In Other Working Capital: 97000000.00
MRNA cash_flow (quarterly, 2025-06-30) — Change In Payable: -47000000.00
MRNA cash_flow (quarterly, 2025-06-30) — Change In Payables And Accrued Expense: -61000000.00
MRNA cash_flow (quarterly, 2025-06-30) — Change In Prepaid Assets: -196000000.00
MRNA cash_flow (quarterly, 2025-06-30) — Change In Receivables: 30000000.00
MRNA cash_flow (quarterly, 2025-06-30) — Change In Working Capital: -297000000.00
MRNA cash_flow (quarterly, 2025-06-30) — Changes In Account Receivables: 30000000.00
MRNA cash_flow (quarterly, 2025-06-30) — Changes In Cash: -346000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Common Stock: 0.00
MRNA balance_sheet (quarterly, 2025-06-30) — Common Stock Equity: 9399000000.00
MRNA cash_flow (quarterly, 2025-06-30) — Common Stock Issuance: 14000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Construction In Progress: 913000000.00
MRNA income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 119000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Current Accrued Expenses: 482000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Current Assets: 6171000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Current Capital Lease Obligation: 43000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Current Debt And Capital Lease Obligation: 43000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Current Deferred Liabilities: 218000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Current Deferred Revenue: 218000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Current Liabilities: 1572000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Current Provisions: 308000000.00
MRNA cash_flow (quarterly, 2025-06-30) — Depreciation Amortization Depletion: 57000000.00
MRNA cash_flow (quarterly, 2025-06-30) — Depreciation And Amortization: 57000000.00
MRNA income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 388000000.00
MRNA income_statement (quarterly, 2025-06-30) — Diluted EPS: -2.13
MRNA income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: -825000000.00
MRNA income_statement (quarterly, 2025-06-30) — EBIT: -817000000.00
MRNA income_statement (quarterly, 2025-06-30) — EBITDA: -760000000.00
MRNA cash_flow (quarterly, 2025-06-30) — Earnings Losses From Equity Investments: 0.00
MRNA cash_flow (quarterly, 2025-06-30) — Effect Of Exchange Rate Changes: 1000000.00
MRNA cash_flow (quarterly, 2025-06-30) — End Cash Position: 1281000000.00
MRNA cash_flow (quarterly, 2025-06-30) — Financing Cash Flow: 9000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Finished Goods: 45000000.00
MRNA cash_flow (quarterly, 2025-06-30) — Free Cash Flow: -922000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Gains Losses Not Affecting Retained Earnings: 23000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Goodwill: 52000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Goodwill And Other Intangible Assets: 100000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Gross Accounts Receivable: 260000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Gross PPE: 3542000000.00
MRNA income_statement (quarterly, 2025-06-30) — Gross Profit: 18000000.00
MRNA income_statement (quarterly, 2025-06-30) — Interest Expense: 1000000.00
MRNA income_statement (quarterly, 2025-06-30) — Interest Expense Non Operating: 1000000.00
MRNA income_statement (quarterly, 2025-06-30) — Interest Income: 81000000.00
MRNA income_statement (quarterly, 2025-06-30) — Interest Income Non Operating: 81000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Inventory: 240000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Invested Capital: 9399000000.00
MRNA cash_flow (quarterly, 2025-06-30) — Investing Cash Flow: 564000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Investmentin Financial Assets: 2374000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Investments And Advances: 2380000000.00
MRNA cash_flow (quarterly, 2025-06-30) — Issuance Of Capital Stock: 14000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Land And Improvements: 59000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Leases: 264000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Long Term Capital Lease Obligation: 698000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Long Term Debt And Capital Lease Obligation: 698000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Long Term Equity Investment: 6000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Machinery Furniture Equipment: 193000000.00
MRNA cash_flow (quarterly, 2025-06-30) — Net Common Stock Issuance: 14000000.00
MRNA income_statement (quarterly, 2025-06-30) — Net Income: -825000000.00
MRNA income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: -825000000.00
MRNA income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: -825000000.00
MRNA income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: -825000000.00
MRNA income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: -825000000.00
MRNA cash_flow (quarterly, 2025-06-30) — Net Income From Continuing Operations: -825000000.00
MRNA income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: -825000000.00
MRNA cash_flow (quarterly, 2025-06-30) — Net Intangibles Purchase And Sale: 0.00
MRNA income_statement (quarterly, 2025-06-30) — Net Interest Income: 80000000.00
MRNA cash_flow (quarterly, 2025-06-30) — Net Investment Purchase And Sale: 567000000.00
MRNA cash_flow (quarterly, 2025-06-30) — Net Issuance Payments Of Debt: -5000000.00
MRNA cash_flow (quarterly, 2025-06-30) — Net Long Term Debt Issuance: -5000000.00
MRNA income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: 80000000.00
MRNA cash_flow (quarterly, 2025-06-30) — Net Other Financing Charges: 0.00
MRNA balance_sheet (quarterly, 2025-06-30) — Net PPE: 2919000000.00
MRNA cash_flow (quarterly, 2025-06-30) — Net PPE Purchase And Sale: -3000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Net Tangible Assets: 9299000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Non Current Accounts Receivable: 99000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Assets: 81000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Liabilities: 65000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Revenue: 65000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Taxes Assets: 81000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Non Current Prepaid Assets: 111000000.00
MRNA income_statement (quarterly, 2025-06-30) — Normalized EBITDA: -760000000.00
MRNA income_statement (quarterly, 2025-06-30) — Normalized Income: -825000000.00
MRNA cash_flow (quarterly, 2025-06-30) — Operating Cash Flow: -919000000.00
MRNA cash_flow (quarterly, 2025-06-30) — Operating Gains Losses: 0.00
MRNA income_statement (quarterly, 2025-06-30) — Operating Income: -907000000.00
MRNA income_statement (quarterly, 2025-06-30) — Operating Revenue: 176000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Ordinary Shares Number: 389000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Other Current Assets: 57000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Other Current Liabilities: 149000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Other Equity Adjustments: 23000000.00
MRNA income_statement (quarterly, 2025-06-30) — Other Income Expense: 9000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Other Intangible Assets: 48000000.00
MRNA cash_flow (quarterly, 2025-06-30) — Other Non Cash Items: 34000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Other Non Current Assets: 149000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Other Non Current Liabilities: 39000000.00
MRNA income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: 9000000.00
MRNA income_statement (quarterly, 2025-06-30) — Other Operating Expenses: -5000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Other Properties: 1315000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Other Receivables: 272000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Other Short Term Investments: 3852000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Payables: 175000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Payables And Accrued Expenses: 657000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Pensionand Other Post Retirement Benefit Plans Current: 197000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Preferred Stock: 0.00
MRNA balance_sheet (quarterly, 2025-06-30) — Prepaid Assets: 286000000.00
MRNA income_statement (quarterly, 2025-06-30) — Pretax Income: -818000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Properties: 0.00
MRNA cash_flow (quarterly, 2025-06-30) — Purchase Of Intangibles: 0.00
MRNA cash_flow (quarterly, 2025-06-30) — Purchase Of Investment: -1295000000.00
MRNA cash_flow (quarterly, 2025-06-30) — Purchase Of PPE: -3000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Raw Materials: 83000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Receivables: 457000000.00
MRNA income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 119000000.00
MRNA income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 57000000.00
MRNA income_statement (quarterly, 2025-06-30) — Research And Development: 700000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Retained Earnings: 8249000000.00
MRNA cash_flow (quarterly, 2025-06-30) — Sale Of Investment: 1862000000.00
MRNA income_statement (quarterly, 2025-06-30) — Selling General And Administration: 230000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Share Issued: 389000000.00
MRNA cash_flow (quarterly, 2025-06-30) — Stock Based Compensation: 130000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Stockholders Equity: 9399000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Tangible Book Value: 9299000000.00
MRNA income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 0.00
MRNA income_statement (quarterly, 2025-06-30) — Tax Provision: 7000000.00
MRNA income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.21
MRNA balance_sheet (quarterly, 2025-06-30) — Taxes Receivable: 102000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Total Assets: 12010000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Total Capitalization: 9399000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Total Debt: 741000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Total Equity Gross Minority Interest: 9399000000.00
MRNA income_statement (quarterly, 2025-06-30) — Total Expenses: 1044000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Total Liabilities Net Minority Interest: 2611000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Total Non Current Assets: 5839000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Total Non Current Liabilities Net Minority Interest: 1039000000.00
MRNA income_statement (quarterly, 2025-06-30) — Total Operating Income As Reported: -907000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Tradeand Other Payables Non Current: 237000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Work In Process: 112000000.00
MRNA balance_sheet (quarterly, 2025-06-30) — Working Capital: 4599000000.00
MRNA income_statement (quarterly, 2025-09-30) — +Operating Expense: 1055000000.00
MRNA income_statement (quarterly, 2025-09-30) — +Total Revenue: 1002000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 267000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Accounts Receivable: 1046000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Accrued Interest Receivable: 40000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Accumulated Depreciation: -671000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Additional Paid In Capital: 1254000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Allowance For Doubtful Accounts Receivable: -978000000.00
MRNA cash_flow (quarterly, 2025-09-30) — Amortization Of Securities: -17000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Available For Sale Securities: 2143000000.00
MRNA income_statement (quarterly, 2025-09-30) — Basic Average Shares: 390000000.00
MRNA income_statement (quarterly, 2025-09-30) — Basic EPS: -0.51
MRNA cash_flow (quarterly, 2025-09-30) — Beginning Cash Position: 1281000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Buildings And Improvements: 1160000000.00
MRNA cash_flow (quarterly, 2025-09-30) — Capital Expenditure: -33000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Capital Lease Obligations: 734000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Capital Stock: 0.00
MRNA balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 1132000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 4504000000.00
MRNA cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Financing Activities: -1000000.00
MRNA cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Investing Activities: 700000000.00
MRNA cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Operating Activities: -847000000.00
MRNA cash_flow (quarterly, 2025-09-30) — Change In Account Payable: 89000000.00
MRNA cash_flow (quarterly, 2025-09-30) — Change In Accrued Expense: 199000000.00
MRNA cash_flow (quarterly, 2025-09-30) — Change In Inventory: -91000000.00
MRNA cash_flow (quarterly, 2025-09-30) — Change In Other Current Assets: 9000000.00
MRNA cash_flow (quarterly, 2025-09-30) — Change In Other Current Liabilities: -117000000.00
MRNA cash_flow (quarterly, 2025-09-30) — Change In Other Working Capital: 40000000.00
MRNA cash_flow (quarterly, 2025-09-30) — Change In Payable: 89000000.00
MRNA cash_flow (quarterly, 2025-09-30) — Change In Payables And Accrued Expense: 288000000.00
MRNA cash_flow (quarterly, 2025-09-30) — Change In Prepaid Assets: 66000000.00
MRNA cash_flow (quarterly, 2025-09-30) — Change In Receivables: -1013000000.00
MRNA cash_flow (quarterly, 2025-09-30) — Change In Working Capital: -818000000.00
MRNA cash_flow (quarterly, 2025-09-30) — Changes In Account Receivables: -1013000000.00
MRNA cash_flow (quarterly, 2025-09-30) — Changes In Cash: -148000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Common Stock: 0.00
MRNA balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 9330000000.00
MRNA cash_flow (quarterly, 2025-09-30) — Common Stock Issuance: 2000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Construction In Progress: 350000000.00
MRNA income_statement (quarterly, 2025-09-30) — Cost Of Revenue: 207000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Current Accrued Expenses: 442000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Current Assets: 6598000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Current Capital Lease Obligation: 48000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Current Debt And Capital Lease Obligation: 48000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Current Deferred Liabilities: 163000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Current Deferred Revenue: 163000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 1681000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Current Provisions: 426000000.00
MRNA cash_flow (quarterly, 2025-09-30) — Depreciation Amortization Depletion: 52000000.00
MRNA cash_flow (quarterly, 2025-09-30) — Depreciation And Amortization: 52000000.00
MRNA income_statement (quarterly, 2025-09-30) — Diluted Average Shares: 390000000.00
MRNA income_statement (quarterly, 2025-09-30) — Diluted EPS: -0.51
MRNA income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: -200000000.00
MRNA income_statement (quarterly, 2025-09-30) — EBIT: -187000000.00
MRNA income_statement (quarterly, 2025-09-30) — EBITDA: -135000000.00
MRNA cash_flow (quarterly, 2025-09-30) — Earnings Losses From Equity Investments: -3000000.00
MRNA cash_flow (quarterly, 2025-09-30) — Effect Of Exchange Rate Changes: 1000000.00
MRNA cash_flow (quarterly, 2025-09-30) — End Cash Position: 1134000000.00
MRNA cash_flow (quarterly, 2025-09-30) — Financing Cash Flow: -1000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Finished Goods: 128000000.00
MRNA cash_flow (quarterly, 2025-09-30) — Free Cash Flow: -880000000.00
MRNA income_statement (quarterly, 2025-09-30) — Gain On Sale Of Security: 4000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Gains Losses Not Affecting Retained Earnings: 27000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Goodwill: 52000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Goodwill And Other Intangible Assets: 99000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Gross Accounts Receivable: 2024000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Gross PPE: 3535000000.00
MRNA income_statement (quarterly, 2025-09-30) — Gross Profit: 795000000.00
MRNA income_statement (quarterly, 2025-09-30) — Interest Expense: 0.00
MRNA income_statement (quarterly, 2025-09-30) — Interest Expense Non Operating: 0.00
MRNA income_statement (quarterly, 2025-09-30) — Interest Income: 73000000.00
MRNA income_statement (quarterly, 2025-09-30) — Interest Income Non Operating: 73000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Inventory: 332000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Invested Capital: 9330000000.00
MRNA cash_flow (quarterly, 2025-09-30) — Investing Cash Flow: 700000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Investmentin Financial Assets: 2143000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Investments And Advances: 2152000000.00
MRNA cash_flow (quarterly, 2025-09-30) — Issuance Of Capital Stock: 2000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Land And Improvements: 78000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Leases: 359000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Long Term Capital Lease Obligation: 686000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Long Term Debt And Capital Lease Obligation: 686000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Long Term Equity Investment: 9000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Machinery Furniture Equipment: 225000000.00
MRNA cash_flow (quarterly, 2025-09-30) — Net Common Stock Issuance: 2000000.00
MRNA income_statement (quarterly, 2025-09-30) — Net Income: -200000000.00
MRNA income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: -200000000.00
MRNA income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: -200000000.00
MRNA income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: -200000000.00
MRNA income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: -200000000.00
MRNA cash_flow (quarterly, 2025-09-30) — Net Income From Continuing Operations: -200000000.00
MRNA income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: -200000000.00
MRNA cash_flow (quarterly, 2025-09-30) — Net Intangibles Purchase And Sale: 0.00
MRNA income_statement (quarterly, 2025-09-30) — Net Interest Income: 73000000.00
MRNA cash_flow (quarterly, 2025-09-30) — Net Investment Purchase And Sale: 733000000.00
MRNA cash_flow (quarterly, 2025-09-30) — Net Issuance Payments Of Debt: -3000000.00
MRNA cash_flow (quarterly, 2025-09-30) — Net Long Term Debt Issuance: -3000000.00
MRNA income_statement (quarterly, 2025-09-30) — Net Non Operating Interest Income Expense: 73000000.00
MRNA cash_flow (quarterly, 2025-09-30) — Net Other Financing Charges: 0.00
MRNA balance_sheet (quarterly, 2025-09-30) — Net PPE: 2864000000.00
MRNA cash_flow (quarterly, 2025-09-30) — Net PPE Purchase And Sale: -33000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: 9231000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Non Current Accounts Receivable: 99000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Assets: 81000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Liabilities: 157000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Revenue: 157000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Assets: 81000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Non Current Prepaid Assets: 105000000.00
MRNA income_statement (quarterly, 2025-09-30) — Normalized EBITDA: -139000000.00
MRNA income_statement (quarterly, 2025-09-30) — Normalized Income: -203160000.00
MRNA cash_flow (quarterly, 2025-09-30) — Operating Cash Flow: -847000000.00
MRNA cash_flow (quarterly, 2025-09-30) — Operating Gains Losses: -3000000.00
MRNA income_statement (quarterly, 2025-09-30) — Operating Income: -260000000.00
MRNA income_statement (quarterly, 2025-09-30) — Operating Revenue: 1971000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 390580775.00
MRNA balance_sheet (quarterly, 2025-09-30) — Other Current Assets: 56000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Other Current Liabilities: 25000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Other Equity Adjustments: 27000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Other Intangible Assets: 47000000.00
MRNA cash_flow (quarterly, 2025-09-30) — Other Non Cash Items: 14000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Other Non Current Assets: 137000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Other Non Current Liabilities: 42000000.00
MRNA income_statement (quarterly, 2025-09-30) — Other Non Operating Income Expenses: -4000000.00
MRNA income_statement (quarterly, 2025-09-30) — Other Operating Expenses: -14000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Other Properties: 1363000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Other Receivables: 204000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Other Short Term Investments: 3372000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Payables: 267000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Payables And Accrued Expenses: 709000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Pensionand Other Post Retirement Benefit Plans Current: 310000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Preferred Stock: 0.00
MRNA balance_sheet (quarterly, 2025-09-30) — Prepaid Assets: 312000000.00
MRNA income_statement (quarterly, 2025-09-30) — Pretax Income: -187000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Properties: 0.00
MRNA cash_flow (quarterly, 2025-09-30) — Purchase Of Intangibles: 0.00
MRNA cash_flow (quarterly, 2025-09-30) — Purchase Of Investment: -1162000000.00
MRNA cash_flow (quarterly, 2025-09-30) — Purchase Of PPE: -33000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Raw Materials: 85000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Receivables: 1394000000.00
MRNA income_statement (quarterly, 2025-09-30) — Reconciled Cost Of Revenue: 207000000.00
MRNA income_statement (quarterly, 2025-09-30) — Reconciled Depreciation: 52000000.00
MRNA income_statement (quarterly, 2025-09-30) — Research And Development: 801000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Retained Earnings: 8049000000.00
MRNA cash_flow (quarterly, 2025-09-30) — Sale Of Investment: 1895000000.00
MRNA income_statement (quarterly, 2025-09-30) — Selling General And Administration: 268000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Share Issued: 390580775.00
MRNA cash_flow (quarterly, 2025-09-30) — Stock Based Compensation: 125000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 9330000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: 9231000000.00
MRNA income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: 840000.00
MRNA income_statement (quarterly, 2025-09-30) — Tax Provision: 13000000.00
MRNA income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.21
MRNA balance_sheet (quarterly, 2025-09-30) — Taxes Receivable: 104000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Total Assets: 12135000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 9330000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Total Debt: 734000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 9330000000.00
MRNA income_statement (quarterly, 2025-09-30) — Total Expenses: 1262000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 2805000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 5537000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 1124000000.00
MRNA income_statement (quarterly, 2025-09-30) — Total Operating Income As Reported: -260000000.00
MRNA income_statement (quarterly, 2025-09-30) — Total Unusual Items: 4000000.00
MRNA income_statement (quarterly, 2025-09-30) — Total Unusual Items Excluding Goodwill: 4000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Tradeand Other Payables Non Current: 239000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Work In Process: 119000000.00
MRNA balance_sheet (quarterly, 2025-09-30) — Working Capital: 4917000000.00
MRNA income_statement (annual, 2025-12-31) — +Operating Expense: 4128000000.00
MRNA income_statement (quarterly, 2025-12-31) — +Operating Expense: 1081000000.00
MRNA income_statement (annual, 2025-12-31) — +Total Revenue: 1922000000.00
MRNA income_statement (quarterly, 2025-12-31) — +Total Revenue: 676000000.00
MRNA balance_sheet (annual, 2025-12-31) — Accounts Payable: 317000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Accounts Payable: 317000000.00
MRNA balance_sheet (annual, 2025-12-31) — Accounts Receivable: 184000000.00
MRNA balance_sheet (quarterly, 2025-12-31) — Accounts Receivable: 184000000.00
MRNA balance_sheet (annual, 2025-12-31) — Accrued Interest Receivable: 42000000.00